Femara 2,5 mg Orifarm

13,18 131,89 

SKU: N/A Category:


Indications for the use of the active substance Letrozole

Early stages of invasive breast cancer whose cells have hormone receptors, in postmenopausal women, as adjuvant therapy. Early stages of invasive breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen for 5 years, as prolonged adjuvant therapy. Disseminated hormone-dependent breast cancer in postmenopausal women (first-line therapy). Disseminated breast cancer with disease recurrence or progression in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy. Hormone-dependent HER-2 negative breast cancer in postmenopausal women as neoadjuvant therapy when chemotherapy is contraindicated and emergency surgery is not required.


The mode of administration and dosing regimen of a given drug depends on its release form and other factors. The optimal dosing regimen is determined by the physician. It is imperative that the dosage form of the drug used is strictly consistent with the indications for use and the dosage regimen.

Additional information

substance active


Amount of substance, mg


formulaire de discharge


1 compressed, mg


Plaquettes thermoformed by package, pieces



Orifarm Ltd

volume de commande

1 blister of 10 compresses, 1 package (10 blisters)


There are no reviews yet.

Be the first to review “Femara 2,5 mg Orifarm”

Your email address will not be published. Required fields are marked *

Select options